AngioDynamics has initiated a comprehensive study to evaluate the efficacy and safety of the AlphaVac Mechanical Aspiration Thrombectomy System...

Takeda will showcase data from its Phase 2b trials and long-term extension study of TAK-861, an investigational orexin receptor...

Cybin Inc., a clinical-stage biotech company, is advancing its clinical programs for neuropsychiatric disorders. The company’s lead programs, CYB003...

Toronto-based Cybin Inc., a clinical-stage neuropsychiatry company focused on developing novel treatments for mental health conditions, has consolidated its...

Massive Bio, an industry leader in AI-powered clinical trial enrollment, has introduced Patient Connect, an innovative portal designed to...

The phase 3 CABINET trial evaluated cabozantinib versus placebo in patients with previously treated neuroendocrine tumors. Data from this...

SubjectWell bolsters its global patient recruitment capabilities by acquiring Trials24. The merger combines SubjectWell’s accuracy, diverse patient pool, and...

DeepCure, a company employing AI for drug discovery, will present preclinical data on their BRD4 Inhibitor, DC-9476, at the...

Ferrer, a B Corp-certified pharmaceutical company, has initiated a Phase II clinical trial, PROSPER, to assess the safety and...

CD137 (4-1BB) is a promising target for cancer immunotherapy. Its ability to stimulate T cells and enhance tumor cell...